| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Fares Ayoub | Q38641831 |
| P2093 | author name string | Jorge Lascano | |
| Hechu Li | |||
| Giuseppe Morelli | |||
| Cesar Trillo-Alvarez | |||
| Charles Blay | |||
| P2860 | cites work | Genetic modifiers of liver disease in cystic fibrosis | Q30418279 |
| Knowledge of adult patients with cystic fibrosis about their illness | Q36505332 | ||
| Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease | Q37887181 | ||
| European Cystic Fibrosis Society Standards of Care: Best Practice guidelines | Q38214213 | ||
| Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis | Q43814867 | ||
| Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease | Q49334378 | ||
| Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity. | Q50717522 | ||
| The Health Care Transition of Youth With Liver Disease into the Adult Health System: Position Paper from ESPGHAN and EASL. | Q52344633 | ||
| Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension. | Q53987384 | ||
| Ursodeoxycholic acid for cystic fibrosis-related liver disease | Q57126201 | ||
| Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria? | Q73517330 | ||
| Liver disease in cystic fibrosis | Q81365513 | ||
| Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients | Q90603976 | ||
| P433 | issue | 5 | |
| P921 | main subject | cystic fibrosis | Q178194 |
| P304 | page(s) | 187-190 | |
| P577 | publication date | 2019-11-01 | |
| P1433 | published in | Clinical liver disease | Q27726171 |
| P1476 | title | Multidisciplinary Care for Cystic Fibrosis Liver Disease: Where Does the Adult Hepatologist Fit In? | |
| P478 | volume | 14 |
Search more.